Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

NCT04106843 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No Participants Registered

Conditions

Locally Advanced Adrenal Gland Pheochromocytoma
Locally Advanced Paraganglioma
Metastatic Adrenal Gland Pheochromocytoma
Metastatic Paraganglioma
Metastatic Parathyroid Gland Carcinoma
Pituitary Gland Carcinoma
Somatostatin Receptor Positive
Stage III Thyroid Gland Medullary Carcinoma AJCC v8
Stage IV Thyroid Gland Medullary Carcinoma AJCC v8
Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8
Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8
Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Unresectable Adrenal Gland Pheochromocytoma
Unresectable Paraganglioma

Interventions

DRUG: Lutetium Lu 177 Dotatate

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]